SS&C Technologies Free cash flow decreased by 53.6% to $293.70M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 13.2%, from $259.50M to $293.70M. Over 4 years (FY 2021 to FY 2025), Free cash flow shows an upward trend with a 4.8% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $368.10M | $369.20M | $463.80M | $172.70M | $252.20M | $286.40M | $359.60M | $244.30M | $315.70M | $226.00M | $372.50M | $174.70M | $374.90M | $310.70M | $466.90M | $259.50M | $350.00M | $421.50M | $633.00M | $293.70M |
| QoQ Change | — | +0.3% | +25.6% | -62.8% | +46.0% | +13.6% | +25.6% | -32.1% | +29.2% | -28.4% | +64.8% | -53.1% | +114.6% | -17.1% | +50.3% | -44.4% | +34.9% | +20.4% | +50.2% | -53.6% |
| YoY Change | — | — | — | — | -31.5% | -22.4% | -22.5% | +41.5% | +25.2% | -21.1% | +3.6% | -28.5% | +18.8% | +37.5% | +25.3% | +48.5% | -6.6% | +35.7% | +35.6% | +13.2% |